Spotlight on iPSC production

The first generation of induced pluripotent stem cells (iPSCs) 10 years ago marked a huge milestone in the field, leading to great progress from disease modeling to development of new therapeutic approaches for numerous conditions. However, only one human trial using iPSCs has been carried out to date, which was halted owing to safety concerns but is set to resume in 2017. Our spotlight on iPSCs, a 2-month focus including journal articles, exclusive features and a panel discussion, will aim to review the current challenges in the production of iPSCs with a focus on consistency, safety and efficacy; clinical applications; and how these therapies are going to evolve and change healthcare in the coming years